The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III trial of ganitumab (GAN, AMG 479) with gemcitabine (G) as first-line treatment (tx) in patients (pts) with metastatic pancreatic cancer (MPC): An analysis of safety from the GAMMA trial (GEM and AMG 479 in Metastatic Adenocarcinoma of the Pancreas).
Charles S. Fuchs
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Enzon; ImClone Systems; Infinity; Mersana; Momenta Pharm; Pfizer; Roche/Genentech; Sanofi
Masafumi Ikeda
Honoraria - Bayer Yakuhin; Dainippon Sumitomo Pharma; Novartis
Gyorgy Bodoky
No relevant relationships to disclose
Takuji Okusaka
Research Funding - Amgen
Expert Testimony - Amgen
Shinichi Ohkawa
No relevant relationships to disclose
Nobumasa Mizuno
No relevant relationships to disclose
Anna Swieboda-Sadlej
No relevant relationships to disclose
Alberto F. Sobrero
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche; Sanofi
Honoraria - Amgen; Merck; Roche; Sanofi
Vincent Haddad
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jesse S. McGreivy
Employment or Leadership Position - Amgen
Stock Ownership - Amgen